The Effect of BRAF Inhibition With Vemurafenib On The Innate and Adaptive Immune Systems in Patients With Unresectable Stage III or Stage IV Melanoma Expressing a V600 BRAF Mutation
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2016
Price : $35 *
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- 31 Aug 2018 Biomarkers information updated
- 15 Mar 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
- 17 Mar 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.